Thalassemia| A Pipeline Analysis Report 2018| Technavio
Jul. 11, 2018
LONDON--(BUSINESS WIRE)--Jul 11, 2018--Technavio has announced its latest pipeline analysis report on the . The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat thalassemia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180711005672/en/
Technavio has published a new report on the drug development pipeline for Thalassemia, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market.
Thalassemia: Market overview
Thalassemia is an inherited blood disorder in which the body produces an abnormal form of hemoglobin. Hemoglobin is a protein in red blood cells that carries oxygen. The disorder can lead to the excessive destruction of red blood cells, thereby causing anemia. Thalassemia can be inherited from one parent or both the parents.
According to a senior market research analyst at Technavio , “Thalassemia is of two types, namely alpha-thalassemia and beta-thalassemia. Alpha-thalassemia occurs when there is a loss of two of the four alpha globin gene therapy variants from the body. Beta-thalassemia occurs when there is a decrease in the production of hemoglobin in the body.”
Thalassemia: Segmentation analysis
This market research report segments the thalassemia market based on therapies employed (monotherapy and monotherapy/combination therapy), RoA (oral, intravenous, subcutaneous, intraosseous, and unknown), therapeutic modality (gene therapy, small molecule, protein, biological, plant-derived, and unknown), targets for drugs under development (HSCs, HbF, TGF-beta proteins, TMPRSS6, HDAC1/2, glycine reuptake, hepcidin, iron, ferroportin, pyruvate kinase, and iron homeostatis), MoA (HbF stimulator, TGF-beta protein regulator, TMPRSS6 inhibitor, glycine reuptake inhibitor, iron chelator, hepcidin stimulator, ferroportin stimulator, pyruvate kinase stimulator, cell replacement, gene transfer, T lymphocyte replacement, and iron homeostatis), and recruitment status (recruiting and active, not yet recruiting).
Monotherapy includes the use of a single drug to treat a disorder or a disease. In the current pipeline, around 69% of the molecules that are being investigated for the treatment of thalassemia are monotherapy.
In case of oral RoA, the delivery of the drug substances is done through the mouth cavity. About 24.15% of the total molecules that are in the current pipeline are expected to be administered orally.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development LandscapeDrugs under development Indications coverage
Drug Development StrategiesTherapies employed RoA Therapeutic modality Geographical coverage
Recruitment StrategiesRecruitment status Gender Age Recruitment volume
Key CompaniesType of players Company overview
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180711005672/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL GENERAL HEALTH
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 07/11/2018 01:02 PM/DISC: 07/11/2018 01:02 PM